Merck Stock Forecast for 2022 - 2025 - 2030

Updated on 05/25/2022

Stock Rating
6 / 10
Price Target
$95.00
Consensus
Outperform
Upside
0.38%
Analysts
19
Stock Rating
6
Upside
0.38%
Analysts
19
Price Target
$95.00

The average price target of $95.00 for Merck's stock set by nineteen distinguished analysts in recent weeks would represent a potential upside of approximately 0.38% from the last closing price in May, 2022 if reached by the end of the year. This potential increase is based on a high estimate of $115.00 and a low estimate of $76.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.

$95.00

0.38% Upside

Outperform
Outperform

Merck Fair Value Forecast for 2022 - 2025 - 2030

In the past three years, Merck's Fair Value has moderately grown, increasing from $65.71 to $91.14 – a growth of 38.71%. The next year looks very promising for Merck, with analysts predicting Fair Value of $110.22 – an increase of 20.93%. Over the next nine years, experts anticipate that MRK's Fair Value will grow at a rate of 25.91%.

2022 Fair Value Forecast
$110.22
2023 Fair Value Forecast
$109.61
2024 Fair Value Forecast
$125.51
2025 Fair Value Forecast
$138.23
2026 Fair Value Forecast
$147.46
2027 Fair Value Forecast
$162.30
2028 Fair Value Forecast
$173.81
2029 Fair Value Forecast
$139.59
2030 Fair Value Forecast
$114.76
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 3
$181.40 $187.12 1.98% 16
LLY Stock Forecast Eli Lilly and Outperform 5
$305.96 $281.95 4.92% 12
ABBV Stock Forecast AbbVie Outperform 6
$149.11 $152.52 12.5% 19
AZN Stock Forecast AstraZeneca PLC Outperform 3
£104.94 £136.08 39% 13
DHR Stock Forecast Danaher Outperform 5
$252.00 $339.17 32.94% 7

Merck Revenue Forecast for 2022 - 2025 - 2030

In the past three years, Merck's Revenue has moderately grown, increasing from $42.29B to $48.70B – a growth of 15.16%. The next year looks very promising for Merck, with analysts predicting Revenue of $57.19B – an increase of 17.43%. Over the next nine years, experts anticipate that MRK's Revenue will grow at a rate of 5.67%.

2022 Rev Forecast
$57.19B
2023 Rev Forecast
$55.63B
2024 Rev Forecast
$58.09B
2025 Rev Forecast
$61.50B
2026 Rev Forecast
$63.75B
2027 Rev Forecast
$65.57B
2028 Rev Forecast
$66.95B
2029 Rev Forecast
$57.16B
2030 Rev Forecast
$51.46B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BMY Stock Forecast Bristol-Myers Squibb Outperform 8
$77.13 $76.69 1.13% 16
AMGN Stock Forecast Amgen Hold 6
$251.89 $246.46 -0.75% 13
GSK Stock Forecast GlaxoSmithKline Outperform 1
£17.64 £16.08 2.04% 11

Merck Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, Merck's DPS has grown by 35.42%, from $1.92 to $2.60. For the next year, analysts are expecting DPS to reach an unimpressive $2.85 – an increase of 9.62%. Over the next nine years, experts predict that DPS will grow by 23.08%.

2022 DPS Forecast
$2.85
2023 DPS Forecast
$3.01
2024 DPS Forecast
$3.27
2025 DPS Forecast
$3.48
2026 DPS Forecast
$3.60
2027 DPS Forecast
$4.04
2028 DPS Forecast
$4.29
2029 DPS Forecast
$3.20
2030 DPS Forecast
$3.20
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
CSL Stock Forecast CSL Outperform 4
$266.28 $228.01 -14.01% 10
MMM Stock Forecast 3M Hold 5
$145.75 $188.41 9.98% 17
GE Stock Forecast General Electric Outperform 2
$74.52 $121.44 43.59% 13

Merck Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, Merck's Free Cash Flow has grown by 16.3%, rising from $8.31B to $9.66B. For next year, analysts predict earnings per share of $15.51B, which would mean an increase of 60.52%. Over the next nine years, experts predict that Merck's Free Cash Flow will grow at a rate of 64.45%.

2022 FCF Forecast
$15.51B
2023 FCF Forecast
$16.98B
2024 FCF Forecast
$18.83B
2025 FCF Forecast
$18.99B
2026 FCF Forecast
$19.57B
2027 FCF Forecast
$20.04B
2028 FCF Forecast
$20.24B
2029 FCF Forecast
$18.90B
2030 FCF Forecast
$15.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
GILD Stock Forecast Gilead Sciences Outperform 5
$64.35 $75.96 6.45% 19
BDX Stock Forecast Becton, Dickinson and Outperform 5
$257.45 $270.20 10.7% 3
BAYN Stock Forecast Bayer Outperform 5
63.29€ 67.79€ 20.08% 14

Merck Net Income Forecast for 2022 - 2025 - 2030

In the past three years, Merck's Net Income has seen a tremendous increase, going from $6.22B to $13.05B – an increase of 109.79%. Next year, analysts are expecting Net Income to reach $18.42B – an increase of 41.16%. Over the next nine years, the forecast is for Net Income to grow by 29.43%.

2022 NI Forecast
$18.42B
2023 NI Forecast
$18.11B
2024 NI Forecast
$20.63B
2025 NI Forecast
$22.38B
2026 NI Forecast
$23.48B
2027 NI Forecast
$25.38B
2028 NI Forecast
$26.54B
2029 NI Forecast
$20.81B
2030 NI Forecast
$16.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAS Stock Forecast BASF Outperform 5
48.76€ 78.27€ 31.26% 16
ILMN Stock Forecast Illumina Outperform 3
$240.26 $376.81 45.68% 0
ALC Stock Forecast Alcon Outperform 0
CHF79.00 CHF0.00 15.3% 14

Merck EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Merck's EBITDA has grown by 29.8%, rising from $14.62B to $18.98B. For next year, analysts predict earnings per share of $24.07B, which would mean an increase of 26.84%. In 2030, professionals predict that Merck's EBITDA will decrease by 3.86%, to just $18.25B.

2022 EBITDA Forecast
$24.07B
2023 EBITDA Forecast
$23.74B
2024 EBITDA Forecast
$26.32B
2025 EBITDA Forecast
$28.06B
2026 EBITDA Forecast
$29.25B
2027 EBITDA Forecast
$31.55B
2028 EBITDA Forecast
$30.36B
2029 EBITDA Forecast
$22.16B
2030 EBITDA Forecast
$18.25B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAX Stock Forecast Baxter International Outperform 5
$73.90 $92.47 21.79% 3
A Stock Forecast Agilent Technologies Outperform 7
$124.41 $172.40 28.61% 2
IDXX Stock Forecast IDEXX Laboratories Outperform 8
$362.16 $648.29 52.56% 2

Merck EBIT Forecast for 2022 - 2025 - 2030

In the past three years, Merck's EBIT has seen significant growth, rising from $10.10B to $15.86B – a growth of 56.97%. In the next year, analysts believe that EBIT will reach a reasonable $21.68B – an increase of 36.73%. For the next nine years, the forecast is for EBIT to grow by 23.04%.

2022 EBIT Forecast
$21.68B
2023 EBIT Forecast
$21.25B
2024 EBIT Forecast
$24.18B
2025 EBIT Forecast
$25.78B
2026 EBIT Forecast
$27.27B
2027 EBIT Forecast
$29.56B
2028 EBIT Forecast
$29.96B
2029 EBIT Forecast
$24.15B
2030 EBIT Forecast
$19.51B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4503 Stock Forecast Astellas Pharma Outperform 2
¥1.80k ¥0.00 33.33% 0
HOLX Stock Forecast Hologic Outperform 2
$78.39 $78.91 0.78% 12
FRE Stock Forecast Fresenius SE & Co. KGaA Outperform 6
32.31€ 50.04€ 23.8% 6

Merck EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the past three years, Merck's EPS has moderately grown, increasing from $4.34 to $6.02 – a growth of 38.71%. The next year looks very promising for Merck, with analysts predicting EPS of $7.28 – an increase of 20.93%. Over the next nine years, experts anticipate that MRK's EPS will grow at a rate of 25.91%.

2022 EPS Forecast
$7.28
2023 EPS Forecast
$7.24
2024 EPS Forecast
$8.29
2025 EPS Forecast
$9.13
2026 EPS Forecast
$9.74
2027 EPS Forecast
$10.72
2028 EPS Forecast
$11.48
2029 EPS Forecast
$9.22
2030 EPS Forecast
$7.58
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
INCY Stock Forecast Incyte Outperform 0
$75.11 $95.69 23.15% 10
AKZA Stock Forecast Akzo Nobel N.V. Outperform 4
93.92€ 113.10€ 15.52% 13
4523 Stock Forecast Eisai Hold 0
¥6.85k ¥0.00 -3.61% 0

© Copyright 2022 | Stock Forecast | All Rights Reserved